Physicochemical Properties
| Molecular Formula | C29H42N6O3 |
| Molecular Weight | 522.68 |
| Exact Mass | 522.331 |
| CAS # | 2227426-37-9 |
| PubChem CID | 134694953 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.4±0.1 g/cm3 |
| Index of Refraction | 1.704 |
| LogP | 1.44 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 38 |
| Complexity | 850 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | C(C1C=CN2C=CN=C2C=1N1CCCN([C@H](C2CCN(C([C@H]3C[C@@H]4CC[C@H]3O4)=O)CC2)CC(=O)N)CC1)C |
| InChi Key | CERHKHQEGFSIHF-OJJQZRKESA-N |
| InChi Code | InChI=1S/C29H42N6O3/c1-2-20-6-12-34-15-9-31-28(34)27(20)33-11-3-10-32(16-17-33)24(19-26(30)36)21-7-13-35(14-8-21)29(37)23-18-22-4-5-25(23)38-22/h6,9,12,15,21-25H,2-5,7-8,10-11,13-14,16-19H2,1H3,(H2,30,36)/t22-,23-,24-,25+/m0/s1 |
| Chemical Name | (3S)-3-[4-(7-ethylimidazo[1,2-a]pyridin-8-yl)-1,4-diazepan-1-yl]-3-[1-[(1R,2S,4S)-7-oxabicyclo[2.2.1]heptane-2-carbonyl]piperidin-4-yl]propanamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | CXCR7 modulator 2 (compound 18) exhibits significant β-arrestin activity (EC50=11 nM) and CXCR7 binding affinity (Ki=13 nM). Additionally, CXCR7 modulator 2 demonstrated enhanced therapeutic index in hERG patch-clamp experiments and enhanced selectivity in the GPCR panel when compared to 11c. In NADPH-supplemented mouse liver microsomes (MLM, 93 μL/min/mg) and hepatocytes (28 μL/min per million cells), CXCR7 modulator 2 displays moderate to high in vitro turnover. In MDCK, on the other hand, it demonstrates low passive absorption permeability II-permeability determination and good water solubility. Rapid absorption of CXCR7 Modulator 2 results in a mean maximum plasma concentration (Cmax) of 682 ng/mL at 0.25 hours (Tmax). 740 ng/mL/h is the equivalent average area under the plasma concentration versus time curve (AUC) [1]. |
| ln Vivo | Administration of isoproterenol for 9 days led in the development of cardiac fibrosis, as demonstrated by an approximately 4-fold increase in collagen deposition relative to controls as determined by Sirius red staining. Treatment with CXCR7 modulator 2 considerably reduced cardiac fibrosis, suggesting the protective effect of CXCR7 modulator 2 regulation of CXCR7 in isoproterenol-induced cardiac damage [1]. |
| References |
[1]. Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. J Med Chem. 2018 Apr 26;61(8):3685-3696. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~478.30 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9132 mL | 9.5661 mL | 19.1322 mL | |
| 5 mM | 0.3826 mL | 1.9132 mL | 3.8264 mL | |
| 10 mM | 0.1913 mL | 0.9566 mL | 1.9132 mL |